Biosidus expands biologics production capacity and strengthens global supply capabilities for agalsidase beta
Buenos Aires, Argentina (ANTARA/PRNewswire) - Biosidus, an Argentine biotechnology company with more than four decades of experience in developing and producing biosimilar medicines, has announced that its new bioreactor facility is now operational. The facility increases the company’s production capacity for biologic medicines while strengthening its ability to meet potential international demand.
The expansion further reinforces Biosidus’s industrial capacity, as healthcare systems place growing emphasis on production reliability, continuity of treatment, and the availability of diverse sources of complex biologic medicines.
Developed and manufactured in Argentina, Biosidus’s agalsidase beta, a biosimilar enzyme replacement therapy for Fabry disease, represents an important milestone in the development of the company’s biotechnology platform and reflects Biosidus’s increasing focus on treating rare diseases.
With this additional production capacity, Biosidus is further strengthening its ability to supply agalsidase beta to international markets and is ready to establish partnerships with stakeholders and health authorities seeking a reliable and sustainable source of agalsidase beta.
“Continuity of treatment is essential, especially for patients living with rare and chronic diseases. This expansion of production capacity further underscores our commitment to providing Biosidus biotechnology solutions to healthcare systems that require reliable and sustainable access to high-quality biologic medicines,” said Mario Koch, Director of Rare Diseases.
Following the launch of agalsidase beta in Argentina in 2025, Biosidus continues to develop the programme for international markets and is prepared to meet specific supply needs in markets where this is permitted under applicable regulatory provisions.
The new bioreactor capacity is part of Biosidus’s strategy to combine scientific excellence, domestic production capabilities, industrial investment, and expansion into international markets to broaden access to complex biologic therapies.
About Biosidus
Biosidus is an Argentine biotechnology company focused on the development, production, and commercialisation of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines for various therapeutic areas.
Source: jawawa.id (https://jawawa.id/newsitem/biosidus-expands-biologics-production-capacity-and-strengthens-global-supply-capabilities-for-agalsidase-beta-1787849581)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5714521/biosidus-memperluas-kapasitas-produksi-obat-biologis-dan-memperkuat-kemampuan-pasokan-global-untuk-agalsidase-beta), translated from Indonesian